北京大学眼科中心于2001年10月成立，由北京大学第一医院、北京大学人民医院、北京大学第三医院眼科共同组成，依托国家重点学科、国家临床重点专科、北京市重点实验室、国家临床药物试验机构等平台，开展眼科临床与基础研究。来自美国约翰霍普金斯大学的曹安民教授、前香港中文大学眼科学系的林顺潮教授分别担任第一届和第二届主任，北京大学的黎晓新教授为现任主任。

    本中心集合了国家重点学科、国家临床重点专科、北京市重点实验室、国家临床药物试验机构和眼科病理等资源，研究方向多元，开展主要眼病的机制研究，关注眼底病、遗传病的准确诊断与干预；建立临床检测与组学研究平台，为感染性、免疫性眼病提供更好的诊疗平台；关注青少年近视防控，探究近视眼的生物力学改变；创建临床眼病和罕见病队列研究，探讨视觉形成与重塑的研究、评估与康复，为更多眼病病人提供帮助。北京大学眼科中心近些年还开展医工交叉项目，聚焦再生医学与组织工程，进一步对视网膜病、青光眼、角膜病的治疗开展探索；与人工智能、材料科学等前沿学科合作开展多项研究。中心的多项研究成果实现转化，开发的新技术开展临床试验。

    北大眼科中心汇聚了北大三家附属医院的眼科科研人员，在2021年中国医学科学院科技量值五年的排名中，人民医院和北医三院眼科位居前10。在全国性学术组织和主要学术期刊中都有学术兼职，包括全国性的中华医学会眼科学会全国主任委员、常委和委员，中国医师协会眼科医师协会会长、常委，中国微循环学会眼科分会副主任委员，以及区域性的北京医学会眼科分会副主任委员、北京眼科学会副主任委员等。中心依托多项科技部重点研发计划、国家自然基金以及省部级基金开展眼科临床与基础研究。近些年，多学科交叉、多院系合作成为必然趋势。北京大学眼科中心与北大、北医、清华、中科院等多个院校合作，强化学科交流，增强多学科人才培养，开展了多项学科交叉研究。干细胞临床试验项目进行北京市卫健委备案申请，开展再生医学与组织工程学探究视网膜病、青光眼、角膜病治疗，以造福更多地患者；联合AI团队，开展AI相关疾病诊断与筛查探究；与清华大学合作研发人眼应用材料；与企业合作，研发眼科诊断与治疗设备及装置；中心多项成果实现转化。

    2022年在研科技部重点研发计划课题和子课题各1项、国家自然科学基金面上项目9项和青年基金6项、北京市科委和卫健委科研项目共8项、学协会科研项目5项、北京大学及医院科研项目21项。2022年获得授权的发明专利9项；2021年杨丽萍教授团队知识产权成功转化1000万，2022年吴慧娟教授知识产权转化631万。洪晶教授团队获得2018年度高等院校科技进步二等奖，张纯教授团队获得2022年度北京市科技进步二等奖。

 

机构负责人：黎晓新教授

联系人：张纯教授

邮箱：zhangc1@yahoo.com

地址：北京市海淀区花园北路49号

 

Peking University Eye Center

 

Peking University Eye Center was founded in 2001. It consists of three ophthalmic departments from the Peking University First Hospital, People Hospital and Third Hospital. As a University research facility, the center has many support platforms including national key discipline, national key clinical specialty, Beijing key laboratories and GCP centers. The center focus on basic and clinical research on visual science. Professor Mark OM Tso from Johns Hopkins University, United States and Professor Dennis SC Lam formerly from the department of Ophthalmology and Visual Science, The Chinese University of Hong Kong served as the first and second directors. Professor Xiaoxin Li from Peking University is the current director.

 

The center has gathered a variety of resources including national key discipline, national key clinical specialty, Beijing key laboratories, GCP and Ocular Pathology.

1. Pathogenies studies of the major eye diseases.

2. Precision medicine on retinal diseases and inherited ocular diseases.

3. Clinical testing platform with genomics and proteomics studies for infectious and immune-related eye diseases.

4. Prevention and investigation of biomechanics of children myopia

5. Establishing a series of clinical cohorts on rare ocular diseases.

6. Investigation of visual formation and reconstruction process, to explore new vision assessment and rehabilitation methods.

In recent years, Peking University Ophthalmic Center has also carried out medical-industrial interdisciplinary projects, focusing on regenerative medicine and tissue engineering, further exploring the treatment for retinopathy, glaucoma, and corneal disease; multiple collaboration has been constructed with artificial intelligence, materials science and other frontier disciplines. A number of patents have been commercialized; new technologies have been carried out in clinical trials.

 

Peking University Eye Center brought together clinic and basic researchers from the three affiliated hospitals of Peking University. The center holds multiple platforms such as national key discipline, national key clinical specialty, Beijing key laboratories and GCP. The ophthalmic department of Peking University Peoples Hospital and Peking University Third Hospital ranked top 10 in Chinese Academy of Medical Sciences’ Accumulative Science and Technology Evaluation Metrics (ASTEM) ranking. Faculties of this center hold posts in national academic organizations and major academic journals, including national posts such as the national chairman, members of the standing committee and committee members of the Ophthalmology Branch of Chinese Medical Association; president and members of the standing committee of the Ophthalmologists Branch of Chinese Medical Doctor Association; vice-chairman of Ocular Microcirculation Branch of Chinese Society of Microcirculation and regional posts such as vice-chairman of Beijing Academy of Ophthalmology. With the support of multiple key research and development programs from the ministry of science and technology, Natural Science Foundation of China and provincial and ministerial funding, this center caries out basic medical and clinical ophthalmology research. Recent years interdisciplinary and multi-department cooperation has become an inevitable trend. Peking University Ophthalmology Center collaborates with Peking University, Peking University Health Science Center, Tsinghua University, Chinese Academy of Sciences and other institutions to strengthen interdisciplinary communication, enhance the development of multidisciplinary expertise and carry out multiple interdisciplinary researches. The center applied for filing with Beijing Municipal Health Commission for the stem cell clinical trial, in order to carrying out regenerative medicine and tissue engineering studies to explore the treatments for retinopathy, glaucoma, and corneal disease, hoping to benefit more patients; collaboration with AI team works on developing new disease screening and diagnose methods using AI technology; collaboration with Tsinghua University helps to develop materials applicable to human eyes; cooperation with enterprises and capital helps to develop diagnostic and treatment equipment. Commercialization of the center’s multiple research findings attract more fundings to establish institute-enterprise joint research and development centers.

 

In the Accumulative Science and Technology Evaluation Metrics (ASTEM) national ranking, two ophthalmology departments from this center ranked eighth and tenth respectively, and both have maintained a stable top ten position for five years.

1. Scientific achievements: Professor Hong Jing's team won the second prize of the 2018 Science and Technology Progress Award in Institutions of higher learning; Professor Zhang Chun's team won the second prize of the 2022 Beijing Science and Technology Progress Award

2. Scientific research projects: In 2022 the center holds 1 new or retained key research and development project and 1 sub-project from the ministry of science and technology, 9 projects funded by National Natural Science Foundation of China, 6 projects funded by the National Science Fund for Distinguished Young Scholars, 8 Beijing Municipal Science and Technology commission’s or Beijing Municipal Health Commission’s project, 5 academic associations’ projects and 21 Peking University and affiliated hospital’s research projects. The annual average amount of scientific research funds is 26 million yuan.

3. Scientific output and commercialization: The Scientific research output have increased significantly in the past five years. In 2022 more than 150 SCI-indexed papers have been published; nine patents have been authorized. In 2021, Professor Yang Liping's team had successfully converted their intellectual property rights for 10 million yuan, and in 2022, Professor Wu Huijuan had converted her intellectual property rights for 6.31 million yuan.

4.  

    

Director: Li Xiaoxin, MD

Contact: Zhang Chun, MD

Email: zhangc1@yahoo.com

Address: No.49, North Garden Road, Haidian, Beijing, Ophthalmology Department of Peking University Third Hospital.